Shanghai Institute of Precision Medicine

undefined

ZHANG Yanjie

Chief physician, Principal investigator

Research direction:Tumor molecular targeted therapy and immunotherapy

E-mail:zhangyanjie@@shsmu.edu.cn

Lab: http://www.shipm.cn/jyjz_web/html/jyjz_English/jyjz_eg_zyj_sysjj/List/index.htm

Research Interests

  • Understanding the genetic and molecular basis underpinning the sensitivity and resistance to cell signaling pathway targeted agents, especially the mTOR signaling, and developing more effective strategies to improve treatment outcomes.

  • By using Patient-derived xenografts (PDX) models, performing target identification, drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies.

  • Exploring predictive/prognostic biomarkers for tumor molecular targeted therapy and immunotherapy in clinical trials.

Education and Work Experience

  • 2010/06-2014/11: Postdoc, Cancer Pharmacology Program, Cancer Institute of New Jersey

  • 2005/09-2008/06: Ph.D. and M.D. of Internal Medicine (Gastrointestinal tumors), Shanghai Jiao Tong University School of Medicine

  • 2000/09-2003/06: Master and M.D. of Internal Medicine (Gastrointestinal tumors), Shanghai Jiao Tong University, School of Medicine

  • 2003/07-Present: Chief physician, Department of Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University, School of Medicine

Selected Publications

  1. Chen B, Du G, Guo J, Zhang Y. Bugs, drugs, and cancer: can the microbiome be a potential therapeutic target for cancer management? Drug Discov Today. 2019, 24(4):1000-1009.

  2. Zhang H, Li X, Yang Y, Zhang Y, Wang HY, Zheng XFS. Significance and Mechanism of Androgen Receptor (AR) Overexpression and AR-mTOR Crosstalk in Hepatocellular Carcinoma. Hepatology. 2018, 67(6):2271-2286.

  3. Huang B, Cai W, Wang Q, Liu F, Xu M, Zhang Y. Gankyrin Drives Malignant Transformation of Gastric Cancer and Alleviates Oxidative Stress via mTORC1 Activation. Oxid Med Cell Longev. 2018, 2018:9480316.

  4. Qin X, Wang J, Wang X, Liu F, Jiang B, Zhang Y. Targeting Rabs as a novel therapeutic strategy for cancer therapy. Drug Discov Today. 2017, 22(8):1139-1147.

  5. Qin X, Wang X, Liu F, Morris LE, Wang X, Jiang B, Zhang YJ. Gankyrin Activates mTORC1 signaling by Accelerating TSC2 Degradation in Colorectal Cancer. Cancer Letters. 2016, 376(1): 83-94.

  6. Zhang Y, Wang X, Qin X, Wang X, Liu F, White E, Zheng XF. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. Ebiomedicine. 2015, 2(12):1944-1956.

  7. Thomas JD, Zhang YJ, Wei YH, Cho JH, Morris LE, Wang HY, Zheng XFS. Rab1A is an mTORC1 Activator and a Colorectal Oncogene. Cancer Cell. 2014, 26(5): 754-769.

  8. Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle. 2012, 11(3):594-603.